Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Deferred Taxes (2016 - 2025)

Historic Deferred Taxes for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to -$8.7 million.

  • Integra Lifesciences Holdings' Deferred Taxes rose 431.27% to -$8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$62.3 million, marking a year-over-year decrease of 11791.47%. This contributed to the annual value of -$20.7 million for FY2024, which is 7443.0% down from last year.
  • According to the latest figures from Q3 2025, Integra Lifesciences Holdings' Deferred Taxes is -$8.7 million, which was up 431.27% from -$44.8 million recorded in Q2 2025.
  • In the past 5 years, Integra Lifesciences Holdings' Deferred Taxes ranged from a high of $10.7 million in Q4 2021 and a low of -$44.8 million during Q2 2025
  • For the 5-year period, Integra Lifesciences Holdings' Deferred Taxes averaged around -$5.0 million, with its median value being -$2.9 million (2024).
  • In the last 5 years, Integra Lifesciences Holdings' Deferred Taxes skyrocketed by 38719.61% in 2022 and then plummeted by 233118.22% in 2025.
  • Integra Lifesciences Holdings' Deferred Taxes (Quarter) stood at $10.7 million in 2021, then crashed by 156.07% to -$6.0 million in 2022, then crashed by 146.48% to -$14.8 million in 2023, then soared by 52.94% to -$7.0 million in 2024, then dropped by 23.83% to -$8.7 million in 2025.
  • Its last three reported values are -$8.7 million in Q3 2025, -$44.8 million for Q2 2025, and -$1.8 million during Q1 2025.